Rheumatoid Arthritis Global Survey 2017

Which of the following best describes your profession? *

Which of the following best describes your profession? Other (please specify)

Which of the following best describes your specialty? *

Rheumatology

Internal medicine/primary care

Other (please specify)

Which of the following best describes your specialty? Other (please specify)

In what country are you currently practicing? *

Please rank your confidence (on a scale of 1 – 4, with 1 being not confident and 4 being very confident) regarding your ability to manage patients who are utilizing the following classes of disease modifying antirheumatic drugs (DMARDs) in clinical practice. *

	1	2	3	4
Conventional synthetic DMARDs [e.g. methotrexate(MTX)]	Conventional synthetic DMARDs [e.g. methotrexate(MTX)] - 1	Conventional synthetic DMARDs [e.g. methotrexate(MTX)] - 2	Conventional synthetic DMARDs [e.g. methotrexate(MTX)] - 3	Conventional synthetic DMARDs [e.g. methotrexate(MTX)] - 4
Tumor necrosis factor targeted monoclonal antibodies (mAB) (e.g. infliximab)	Tumor necrosis factor targeted monoclonal antibodies (mAB) (e.g. infliximab) - 1	Tumor necrosis factor targeted monoclonal antibodies (mAB) (e.g. infliximab) - 2	Tumor necrosis factor targeted monoclonal antibodies (mAB) (e.g. infliximab) - 3	Tumor necrosis factor targeted monoclonal antibodies (mAB) (e.g. infliximab) - 4
CD-20 directed mABs (e.g. rituximab)	CD-20 directed mABs (e.g. rituximab) - 1	CD-20 directed mABs (e.g. rituximab) - 2	CD-20 directed mABs (e.g. rituximab) - 3	CD-20 directed mABs (e.g. rituximab) - 4
CTLA-4 targeted therapy (e.g. abatacept)	CTLA-4 targeted therapy (e.g. abatacept) - 1	CTLA-4 targeted therapy (e.g. abatacept) - 2	CTLA-4 targeted therapy (e.g. abatacept) - 3	CTLA-4 targeted therapy (e.g. abatacept) - 4
Il-6 targeted mABs (e.g.tocilizumab)	Il-6 targeted mABs (e.g.tocilizumab) - 1	Il-6 targeted mABs (e.g.tocilizumab) - 2	Il-6 targeted mABs (e.g.tocilizumab) - 3	Il-6 targeted mABs (e.g.tocilizumab) - 4
JAK inhibitors (e.g. tofacitinib)	JAK inhibitors (e.g. tofacitinib) - 1	JAK inhibitors (e.g. tofacitinib) - 2	JAK inhibitors (e.g. tofacitinib) - 3	JAK inhibitors (e.g. tofacitinib) - 4

Please rank your confidence (on a scale of 1 – 4, with 1 being not confident and 4 being very confident) regarding your ability to assess the following disease control related outcomes as part as ongoing management and treatment response assessment in your patients with RA? *

	1	2	3	4
Serum-based markers of inflammation (e.g. ESR, CRP, RF)	Serum-based markers of inflammation (e.g. ESR, CRP, RF) - 1	Serum-based markers of inflammation (e.g. ESR, CRP, RF) - 2	Serum-based markers of inflammation (e.g. ESR, CRP, RF) - 3	Serum-based markers of inflammation (e.g. ESR, CRP, RF) - 4
X-ray imaging	X-ray imaging - 1	X-ray imaging - 2	X-ray imaging - 3	X-ray imaging - 4
MRI and/or ultrasound imaging	MRI and/or ultrasound imaging - 1	MRI and/or ultrasound imaging - 2	MRI and/or ultrasound imaging - 3	MRI and/or ultrasound imaging - 4
Joint swelling/tenderness	Joint swelling/tenderness - 1	Joint swelling/tenderness - 2	Joint swelling/tenderness - 3	Joint swelling/tenderness - 4
Clinical RA scores (e.g. DAS28, CDAI)	Clinical RA scores (e.g. DAS28, CDAI) - 1	Clinical RA scores (e.g. DAS28, CDAI) - 2	Clinical RA scores (e.g. DAS28, CDAI) - 3	Clinical RA scores (e.g. DAS28, CDAI) - 4
Patient reported physical function and global assessment	Patient reported physical function and global assessment - 1	Patient reported physical function and global assessment - 2	Patient reported physical function and global assessment - 3	Patient reported physical function and global assessment - 4
Patient reported pain, fatigue and quality of life	Patient reported pain, fatigue and quality of life - 1	Patient reported pain, fatigue and quality of life - 2	Patient reported pain, fatigue and quality of life - 3	Patient reported pain, fatigue and quality of life - 4

How knowledgeable are you about available/emerging literature regarding the role of cytokines and cytokine signaling in the pathogenesis and treatment of RA? *

Not knowledgeable

Somewhat knowledgeable

Moderately knowledgeable

Very knowledgeable

How knowledgeable are you about the available/emerging research and clinical trial data on IL-6 inhibitors for the treatment of RA? *

Not knowledgeable

Somewhat knowledgeable

Moderately knowledgeable

Very knowledgeable

How confident are you in your ability (on a scale of 1 – 4, with 1 being not confident and 4 being very confident) to individualize DMARD treatment for the following types of RA patients? *

	1	2	3	4
Patient intolerant or refractory to MTX monotherapy	Patient intolerant or refractory to MTX monotherapy - 1	Patient intolerant or refractory to MTX monotherapy - 2	Patient intolerant or refractory to MTX monotherapy - 3	Patient intolerant or refractory to MTX monotherapy - 4
Patient intolerant or refractory to csDMARD combination therapy	Patient intolerant or refractory to csDMARD combination therapy - 1	Patient intolerant or refractory to csDMARD combination therapy - 2	Patient intolerant or refractory to csDMARD combination therapy - 3	Patient intolerant or refractory to csDMARD combination therapy - 4
Patient intolerant or refractory to TNF-inhibition therapy (with or without MTX)	Patient intolerant or refractory to TNF-inhibition therapy (with or without MTX) - 1	Patient intolerant or refractory to TNF-inhibition therapy (with or without MTX) - 2	Patient intolerant or refractory to TNF-inhibition therapy (with or without MTX) - 3	Patient intolerant or refractory to TNF-inhibition therapy (with or without MTX) - 4

Which of the following do you feel represents the BEST course of action for a RA patient who displays an inadequate response to a TNF inhibitor? *

Continue treatment as is and reassess for improvement periodically

Switch the patient to a different TNF inhibitor

Switch the patient to a CD20 mAB

Switch the patient to a CTLA-4 therapy

Switch the patient to a IL-6 mAB

Switch the patient to a JAK inhibitor

Unsure

Other (please specify)

Which of the following do you feel represents the BEST course of action for a RA patient who displays an inadequate response to a TNF inhibitor? Other (please specify)

What are your most significant educational needs regarding the diagnosis, treatment and overall management of your patients with RA?

If you are interested in participating in the raffle for a $100/€100 Amazon gift card, please fill out the following:

First Name:

Last Name:

Email:

You are here

Rheumatoid Arthritis Global Survey 2017